• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Payer Needs and Strategies for Evaluating and Covering PDTs

Opinion
Video

Panelists delve into the data and the cost-saving evidence required by payers to cover prescription digital therapeutics (PDTs), outline the decision-making process followed by payers, and share best practices observed in real-world to ensure the successful implementation of PDTs.

Related Videos
Stephanie L. Graff, MD, an expert on breast cancer
B. Joy Snider, MD, PhD, and Maria Lopes, MD, MS
A panel of 5 experts on Alzheimer disease
Video 1 - "Differentiating PDTs from Wellness Apps and Evaluating Efficacy"
Chris Pagnani, MD, PC
Video 4 - "Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer"
Video 3 - "The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer"
Screenshot of Stephen Freedland, MD, during a video interview
"Integrating New PAH Therapies into Clinical Practice"
"Clinical Evidence for Emerging PAH Therapies"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.